Bedrijfsoverzicht
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of DNA medicines designed to treat and protect individuals from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a reliance on scientific innovation, extensive research and development cycles, and a high degree of regulatory scrutiny for product approvals. At the current time, the firm employs 112 people and holds a market capitalization of $86.49M, while reporting a trailing twelve-month revenue of $65,343. These financial figures indicate that the company is a small-cap entity operating with a very limited revenue base relative to its market valuation, suggesting a position in the early-stage or developmental phase of its business lifecycle where capital allocation focuses on R&D rather than profit generation.
Financiële gezondheid
The company reported a revenue of $65,343 over the trailing twelve months, yet simultaneously recorded a net income of -$84,945,904 and an EBITDA of -$84,945,904. The substantial gap between the negligible revenue and the significant net loss reveals a cost structure dominated by heavy operational expenses, likely driven by research and development activities that exceed current sales income. Free cash flow stands at -$38,681,548, which indicates that the company is currently burning cash and lacks the internal financial flexibility to fund operations or growth without external capital injections. All three margin metrics reflect this financial reality, with a gross margin of 0.0%, an operating margin of -132871.3%, and a profit margin of 0.0%. These negative or zero margin levels signify that the company is not yet achieving operational profitability and that its cost of goods sold or operating expenses are far outpacing its revenue generation. On the balance sheet, the firm holds $58.51M in cash against $9.37M in debt, supported by a debt-to-equity ratio of 38.88, which suggests a leveraged position where debt exceeds equity significantly despite the absolute debt amount being lower than cash reserves. The current ratio is 1.40, indicating that the company possesses 1.40 dollars of current assets for every dollar of current liabilities, which points to a moderate level of short-term liquidity sufficient to cover immediate obligations. Return on Equity is -183.5% and Return on Assets is -57.9%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or in utilizing its assets to produce income.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -1.64, which implies that the market expects earnings to remain negative in the near term or that valuation models are adjusted for pre-profitability stages. The price-to-book ratio is 3.04, indicating that the stock is trading at a significant premium relative to its tangible book value, a situation often seen in biotechnology firms where future pipeline potential justifies a higher valuation despite current losses. Alternative valuation measures such as the price-to-sales ratio of 1323.59 and an EV/EBITDA of -0.28 further highlight the disconnect between current financial performance and market pricing, suggesting investors are valuing the company based on potential future milestones rather than current cash flows. The stock has experienced considerable price volatility over the past year, trading between a 52-week high of $2.98 and a 52-week low of $1.03. Based on the recent market data context, the current price sits within this range, reflecting the speculative nature of the asset. The beta value of 1.70 indicates that the stock's price volatility is significantly higher than that of the broader market, moving 1.70 times as much as the market index on average.
Growth & Income
The company's revenue growth year-over-year is -100.0%, while earnings growth year-over-year is N/A due to the absence of positive earnings in the prior period. The decline in revenue to near zero combined with the lack of positive earnings growth suggests that the company is not currently expanding its commercial footprint but is instead focused on sustaining operations until product approvals or commercial launches can occur. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, implying that any generated earnings would be reinvested into research and development or used to extend the life of the company through cash reserves. This reinvestment strategy is typical for pre-profitability biotechnology firms that prioritize capital expenditure for clinical trials over shareholder distributions. The overall growth and income profile is characterized by a lack of current commercial expansion and a reliance on existing cash reserves to fund future development rather than generating immediate returns or income for investors.